Aeterna Zentaris Shares Up 25% Following Deal Between Novo Nordisk, Strongbridge For Rights To MACRILEN; Aeterna Zentaris Receives 15-18% Royalties From Sales Of MACRILEN In US, Canada
Benzinga Newsdesk